Editorial Assistance Research Articles

882TiP Subcutaneous vs intravenous nivolumab in patients with melanoma following complete resection

Nivolumab (NIVO), a programmed death-1 immune checkpoint inhibitor, is approved globally as an effective treatment across multiple cancer types. Several studies are investigating subcutaneous (SC) NIVO, co-formulated with recombinant human hyaluronidase PH20 (rHuPH20), as it may benefit patients, clinicians, and the healthcare system. Patients with cancer often prefer SC over IV administration. SC dosing may alleviate the need for IV vein ports, lower the risk of dosing errors, allow more patient flexibility, and reduce dose preparation and administration times, thereby optimizing occupancy in infusion centres. In CheckMate 8KX, SC NIVO + rHuPH20 was well tolerated in patients with different solid tumours and exposures were comparable to IV NIVO 3 mg/kg Q2W (from historical data). Investigations of SC NIVO vs IV NIVO in patients with clear cell renal cell carcinoma (phase 3 CheckMate 67T study) or melanoma following complete resection are ongoing. CheckMate 6GE is a multicentre, randomized, open-label, phase 3 study evaluating the pharmacokinetic (PK) noninferiority of SC NIVO + rHuPH20 vs IV NIVO in patients with melanoma following complete resection. Inclusion criteria are stage IIIA/B/C/D or stage IV melanoma, complete resection ≤ 12 weeks before randomization or treatment assignment, and ECOG performance status ≤ 1. Key exclusion criteria include a history of uveal/mucosal melanoma, untreated/unresected CNS metastases, concurrent malignancy or history of prior malignancy active ≤ 2 years before randomization or treatment assignment, known or suspected autoimmune disease, serious/uncontrolled medical disorder 4 weeks before screening, and prior immunotherapy. Patients (N ≈ 286) are randomized (1:1) to receive SC NIVO or IV NIVO in part 1 (stratified by stage [IIIA/B vs IIIC/D/IV] and weight [< 80 kg vs ≥ 80 kg]) or enrolled in the part 2 PK cohort. PK, safety, efficacy, immunogenicity, and cancer treatment satisfaction will be evaluated (Table).Table: 882TiPPrimary endpointsTime-averaged NIVO serum concentration over the first 28 daysCmin at steady stateSecondary endpointsSafety and tolerability, eg, AEs, serious AEs, immune-mediated AEs, death, administration-related reactions, laboratory abnormalitiesRecurrence-free survivalOverall survivalAdditional PK parameters: Cmin on Day 28, Cmax after the first dose, time to Cmax after the first dose, Cmax at steady state, time-averaged NIVO serum concentration at steady stateImmunogenicity (anti-NIVO and neutralizing antibodies)Cancer Treatment Satisfaction QuestionnaireAE, adverse event; Cmax, maximum NIVO serum concentration; Cmin, minimum NIVO serum concentration. Open table in a new tab AE, adverse event; Cmax, maximum NIVO serum concentration; Cmin, minimum NIVO serum concentration. NCT05297565. Professional medical writing and editorial assistance was provided by George Hsu, PhD, and Matthew Weddig, BA, of Spark Medica Inc., funded by Bristol Myers Squibb. Bristol Myers Squibb.

Humbled to Serve.

Humbled to Serve.

Humbled to Serve.

Humbled to Serve.

Letter from Randal Jelks

Letter from Randal Jelks Randal Maurice Jelks I began my journey with AMSJ with a conversation with the former co-editor David Katzman in the late fall of 2008. He asked me if I would be interested in joining the editorial team since he would be retiring. I was taken by surprise. I had to think about the conversation at some length. My only editorial experience had been being the editor of my high school annual. Frankly, I had never seen editing an academic journal in my future, just as I had never seen being a professional academic in my future either. After consulting with my PhD mentor and other colleagues I decided it was an opportunity that I should not pass up. Here was an opportunity to intellectually shape a field of study. Editors in the academy are often minimized as service workers, but I viewed editing as being far more engaging than its traditional relegation. As an editor, I viewed myself as an intellectual midwife assisting humanities scholars to give birth to ideas regarding aesthetics, culture, disabilities, politics—past, present and future. As an intellectual midwife it has been such a joy to help guide so many scholarly births that have become books and ongoing discussions in the field of American Studies. More significantly, I was fortunate to join a journal that had been in operation since 1960 with support by the Mid-America American Studies Associations (MAASA), KU American Studies Department and in-kind by the University of Kansas Libraries and the University’s college of Liberal, Arts, and Science. And even more fortunately, I got to work with my distinguish colleague Sherrie Tucker as my senior co-editor. Since 2009 Sherrie has taught me what it means to be truly democratic and respectful of all ideas that come through submissions, even [End Page 7] when we knew they did not fit our journal. She has been a model scholar, colleague and friend. Working with her and learning from her genius has been worth the “price of the ticket.” Finally, the journal has given the opportunity to work with outstanding graduate and undergraduate students who have served as our assistant editors, managing editors, and media production assistants. All the students kept me fresh and attuned to forthcoming trends in every way. My thirteen years of co-editing AMSJ has been blissful. It is time to move on and accomplish other goals—writing more books, documentary film producing, and enjoying the fruits of my labor. I thank everyone for the successes we have achieved together at AMSJ. For me, it has been an lifetime opportunity and I am eternally grateful. [End Page 8] Copyright © 2022 Mid-America American Studies Association

A Phase Ib Dose-finding Study of Panobinostat and Ruxolitinib in Myelofibrosis.

A Phase Ib Dose-finding Study of Panobinostat and Ruxolitinib in Myelofibrosis.

The CONTROL study: A randomized, double-blind vehicle-controlled phase 2b study of novel topical isotretinoin formulation demonstrates improvement in recessive X-linked and autosomal recessive lamellar congenital ichthyosis

The CONTROL study: A randomized, double-blind vehicle-controlled phase 2b study of novel topical isotretinoin formulation demonstrates improvement in recessive X-linked and autosomal recessive lamellar congenital ichthyosis

The OECD/G20 Global Minimum Tax and Dispute Resolution: A Workable Solution Based on Article 25(3) of the OECD Model, the Principle of Reciprocity and the GloBE Model Rules The authors wish to thank the anonymous peer reviewers for their comments as well as the editor-in-chief of the World Tax Journal, Professor Pasquale Pistone, for the opportunity to publish in this

The implementation of the G20/OECD global minimum tax (“GloBE”) raises an immediate and practical challenge in terms of dispute resolution. On the one hand, the GloBE framework will require an unprecedented degree of coordination between jurisdictions with naturally a high potential for bilateral and multilateral disputes. On the other hand, it is foreseen that the GloBE rules will not be incorporated into a Multilateral Convention. Rather, the GloBE architecture will be exclusively transposed into domestic laws through so-called “model rules”. Therefore, at least in an initial phase, no ad hoc international binding dispute resolution mechanism will be available to solve GloBE disputes. In order to address this pressing challenge, this article proposes a readily workable solution to solve GloBE disputes without the need for a Multilateral Convention. The model advocated here consists in a (i) reinforced interpretation of article 25(3) second sentence of the OECD Model on the basis of a subsequent practice (article 31(3)(b) of the VCLT), (ii) a domestic dispute resolution mechanism incorporated into the model rules and mirroring article 25(3) of the OECD Model which would also (iii) apply to non-treaty situations on the basis of the principle of reciprocity and which would (iv) rely on the Convention on Mutual Administrative Assistance in Tax Matters. The authors find that the proposed framework is particularly in line with the object and purpose of the GloBE Model Rules which are to operate between jurisdictions as “mirror legislations” and in a synchronized fashion. This solution may also be combined with other mechanisms currently discussed to simplify and enhance the certainty of the GloBE framework for both MNE groups and tax administrations.

Increased neutrophil infiltration as a body-wide effect in pancreatic cancer development.

Increased neutrophil infiltration as a body-wide effect in pancreatic cancer development.

P-12 A phase 3 study of nivolumab (NIVO), NIVO + ipilimumab (IPI), or chemotherapy for microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC): CheckMate 8HW

Patients with MSI-H/dMMR mCRC treated with chemotherapy have poorer outcomes than patients with microsatellite stable/MMR proficient mCRC. Pembrolizumab monotherapy is approved in multiple countries as first-line therapy for patients with MSI-H/dMMR mCRC; however, despite observed clinical benefit vs chemotherapy, the 24-month progression-free survival (PFS) rate was 48% (Andre et al. NEJM 2020). NIVO (anti–programmed death 1 [PD-1]) and IPI (anti–cytotoxic T lymphocyte antigen-4 [CTLA-4]) are immune checkpoint inhibitors with distinct but complementary mechanisms. NIVO±IPI is approved in previously treated patients with MSI-H/dMMR mCRC in the US, EU, and Japan, based on findings from the phase 2, non-randomized, multicohort CheckMate 142 study. Indirect comparisons suggest that NIVO (3 mg/kg) + IPI (1 mg/kg) provides improved clinical benefit vs NIVO (investigator-assessed [INV] objective response rate [ORR] 55% vs 31%; 12-month INV PFS rate 71% vs 50%; 12-month overall survival [OS] rate 85% vs 73%) with a favorable benefit-risk profile for previously treated MSI-H/dMMR mCRC (Overman et al. JCO 2018). NIVO+IPI also demonstrated robust and durable clinical benefit and was well tolerated for the first-line treatment of MSI-H/dMMR mCRC (INV ORR 69%; 24-month INV PFS rate 74%; 24-month OS rate 79%; Lenz et al. JCO 2022). To date, no prospective phase 3 studies have reported results for anti–PD-1 + anti–CTLA-4 vs chemotherapy or anti–PD-1/programmed death ligand 1 (PD-L1) monotherapy in MSI-H/dMMR mCRC. CheckMate 8HW (NCT04008030) is an international, multicenter, open-label, randomized, phase 3 study designed to compare the efficacy and safety of NIVO+IPI to chemotherapy or NIVO in patients with MSI-H/dMMR mCRC. Approximately 748 patients across 23 countries aged ≥18 years with histologically confirmed recurrent or mCRC that is not amenable to surgery, irrespective of prior treatment with chemotherapy and/or targeted agents, with known tumor MSI-H or dMMR status and ECOG performance status ≤1 will be randomized to receive NIVO, NIVO+IPI, or investigator’s choice chemotherapy (patients in the chemotherapy arm can receive NIVO+IPI upon progression). The dual primary endpoints are PFS, assessed by blinded independent central review (BICR), for NIVO+IPI vs NIVO across all lines and NIVO+IPI vs chemotherapy in the first-line setting in patients with centrally confirmed MSI-H/dMMR mCRC. Other key endpoints include PFS by BICR for NIVO+IPI vs NIVO in the first-line setting, PFS by INV, ORR by BICR, OS, and safety. Recruitment of patients in the first-line setting is ongoing. NCT04008030. All authors contributed to and approved the abstract; writing and editorial assistance was provided by Andrew Scott, PharmD, of Parexel International, funded by Bristol Myers Squibb . Bristol Myers Squibb.

P-298 Open-label, randomized, phase 3 study of first-line lenvatinib plus pembrolizumab plus chemotherapy in esophageal squamous cell carcinoma: LEAP-014 trial in progress

Recent data from the KEYNOTE-590 study demonstrated the superiority of pembrolizumab plus chemotherapy compared with chemotherapy as first-line treatment for unresectable locally advanced recurrent or metastatic adenocarcinoma or squamous cell carcinoma of the esophagus, or advanced/metastatic Siewert type 1 adenocarcinoma of the gastroesophageal junction. Prior data also suggest promising antitumor activity of lenvatinib plus pembrolizumab in advanced solid tumors. LEAP-014 (NCT04949256) is a randomized, 2-part, open-label, phase 3 study that will evaluate the efficacy and safety of first-line lenvatinib plus pembrolizumab plus chemotherapy versus pembrolizumab plus chemotherapy in patients with metastatic esophageal squamous cell carcinoma (ESCC). Key eligibility criteria include metastatic ESCC, measurable disease per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1), and Eastern Cooperative Oncology Group performance status ≤1. In part 1 (safety run-in), ∼6 patients will be treated for induction with intravenous (IV) pembrolizumab 400 mg every 6 weeks (Q6W) for 2 cycles plus oral lenvatinib 8 mg daily (QD) plus IV 5-fluorouracil (FU; 4000 mg/m2 on days 1-5) plus IV cisplatin (80 mg/m2 ) (FP) for 4 cycles and ∼6 patients in China, Hong, Republic of Korea, and Taiwan will be treated for induction with IV pembrolizumab 400 mg Q6W for 2 cycles plus oral lenvatinib 8 mg QD plus IV paclitaxel (175 mg/m2 ) plus IV cisplatin (75 mg/m2 ) (TP) for 4 cycles. All 12 patients will be treated for consolidation with pembrolizumab 400 mg Q6W for ≤16 doses plus lenvatinib 20 mg QD and closely monitored for 21 days after the first dose of study intervention for dose-limiting toxicities. In part 2 (main study), approximately 850 patients will be randomly assigned 1:1 to induction with pembrolizumab plus lenvatinib plus chemotherapy (FP or mFOLFOX6 [Q2W for 6 cycles {IV oxaliplatin 85 mg/m2 plus bolus IV 5-FU 400 mg/m2 plus continuous IV 5-FU 2400 mg/m2 plus IV leucovorin 400 mg/m2 or IV levoleucovorin 200 mg/m2}] or TP [China, Hong Kong, Republic of Korea, and Taiwan only]) followed by consolidation with pembrolizumab plus lenvatinib (arm 1) or pembrolizumab plus chemotherapy (FP, mFOLFOX6, or TP [China, Hong, Republic of Korea, and Taiwan only]; arm 2). Randomization will be stratified by PD-L1 combined positive score (CPS; ≥10 vs < 10), region (East Asia vs North America and Western Europe vs rest of world), and chemotherapy backbone (FP vs TP vs mFOLFOX6). Treatment will continue until disease progression, unacceptable toxicity, or withdrawal of consent. Tumor imaging assessment will be performed Q6W for ≤1 year and Q9W thereafter. In part 1, the primary end point is safety and tolerability. In part 2, the dual primary end points are overall survival and progression-free survival (per RECIST v1.1 assessed by blinded independent central review [BICR]); secondary end points include objective response rate and duration of response (per RECIST v1.1 assessed by BICR) and safety and tolerability. Enrollment in this trial is ongoing. ClinicalTrials.gov Identifier, NCT04949256. Medical writing and/or editorial assistance was provided by Lauren D’Angelo, PhD of ApotheCom (Yardley, PA, USA). This assistance was funded by Merck Sharp & Dohme Corp, a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA, and Eisai Inc., Woodcliff Lake, NJ, USA. Merck Sharp & Dohme Corp, a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA, and Eisai Inc., Woodcliff Lake, NJ, USA.

Against Nausea, and: Radio Softly

Against Nausea, and: Radio Softly Emily Kristin Anderson (bio) Against Nausea Dizzy with blood-smellI tell the radio I should stay a little longer in the lightning,body rigid in the bathroom. I have this weak system—a wholelife of last minutes losing traction, disoriented in spots of light.I could be the wild girl behind the telephone, the weekendthunder pressing on illness, the miracle you invented in the car.I've been sick. On my way back I don't see unmoving thingsglistening in the rain. This is an erasure poem. Source Material: Crichton, Michael. Jurassic Park. Mass Market ed. Ballantine, 2015. 211-225. Print. [End Page 151] Radio Softly I've listened to the living, spent dayslying silent and hot in hellish calm, bubblingwith language. Distantly, the video turned on, that light extendingbackward. I'll wait— it's unpleasant but I exhaled, the anxietyof human waking pressed against me. I felt a whisperon dry lips, two decades slipping into a rabbit hole withoutstretched hands. Lost in a shifting body, I have tostay here, too rough in the center. This is an erasure poem. Source Material: Crichton, Michael. Jurassic Park. Mass Market ed. Ballantine, 2015. 421-435. Print. [End Page 152] Emily Kristin Anderson Emily Kristin Anderson is a poet and glitter enthusiast living mostly at a Starbucks somewhere in Austin, Texas. She is the editor of Come as You Are, an anthology of writing on 1990s pop culture, and her work has been widely published in magazines. She is the author of nine chapbooks of poetry, including A Guide for the Practical Abductee; Pray, Pray, Pray: poems I wrote to Prince in the middle of the night; We're Doing Witchcraft; 17 seventeen XVII; and Behind, All You've Got. Anderson is a poetry reader for Cotton Xenomorph and an editorial assistant at Porkbelly Press. Once upon a time she worked nights at the New Yorker. Copyright © 2022 University of Nebraska Press

Editorial Assistants and Acknowledgments

"Editorial Assistants and Acknowledgments." Contemporary French and Francophone Studies, 26(3), p. 349

Work It

The goal of this paper is to document how labour is divided and compensated (both monetarily and non-monetarily) in Canadian non-commercial scholarly journals. This study informs future research on sustainability in non-commercial academic publishing. As labour is essential for the continued success of these journals, understanding the extent (i.e., how many positions, how many hours per position), scope (i.e., which tasks are undertaken and who is responsible for them), and cost (monetary or non-monetary) of this labour will be critical in ensuring the sustainability of non-commercial academic journals in Canada. To investigate current practices, the authors distributed a survey to 484 Canadian journals meeting the above inclusion criteria. The survey was composed of two sections: how labour is divided at a journal (i.e., how many positions are there, what are the responsibilities of these positions, and how many work hours per week are dedicated to these positions) and compensation (i.e., does the journal provide monetary or non-monetary compensation to members of its editorial team, which positions receive compensation, and what is the source of these funds). The authors received 119 responses, for a 25 percent response rate. Among the main findings are that the majority of respondents compensate at least one journal position and that the source of these funds comes primarily from sponsoring organizations (i.e., affiliated institutional/university departments and scholarly associations). Additional findings include that the top three most commonly compensated positions are copyeditor, editorial assistant, and managing editor. Compensated positions such as translator, graphic designer, and copyeditor are often contracted out. Task distribution amongst editorial team members varies; however, editors-in-chief and managing editors are responsible for the greatest variety of tasks. Editorial assistants and managing editors tend to work more hours than other positions. Additionally, journal production was related to editorial team size, with larger teams producing more volumes on average than smaller ones. Recurring themes in free-text comments were large workloads, lack of compensation, and lack of recognition. This paper provides empirical evidence of the extent and variation of labour and compensation in Canadian non-commercial scholarly publishing. It provides data on current non-commercial journal practices which will be of interest to library publishers, journal editors, and other stakeholders in Canadian scholarly publishing.

From the Editor's Desk

From the Editor's Desk Edward Ousselin, Editor in Chief I am pleased to announce that the AATF has officially designated Carine Bourget (University of Arizona) as the next Editor in Chief of the French Review. Her term will begin on July 1, with Vol. 96. Until then, since the editorial activities related to each issue of our journal begin at least nine months before publication, there is a transitional period, during which we work together. Congratulations and welcome, Carine. As for me, after five years as Review Editor and twelve years as Editor in Chief, it is time to say goodbye. The French Review has long been an important part of my professional life, ever since I started submitting articles and reviews when I was working on my dissertation. It should be noted that this journal (along with the AATF) will celebrate its centennial in 2027. A long list of distinguished colleagues have served in various editorial capacities since the French Review was first published (among them was my predecessor and mentor, Chris Pinet, bien trop tôt disparu). It has been an honor to be a part of this journal's editorial team. There are many people to whom I would like to give thanks. First, those with whom I have worked the most closely on a regular basis. Michèle Bissière, Nathalie Degroult, and Michel Gueldry have each served as Managing Editor. I am deeply grateful for their dedication and professionalism. More than once, each of them, to my relief and embarrassment, has caught mistakes that I had allowed to slip by. The same can be said for our Typesetter, Ronnie Moore <http://www.westypebookdesigns.com>, who consistently produces excellent work, often on tight schedules. Like Michèle, Nathalie, and Michel, Ronnie has been extraordinarily calm and patient when I let a typographical error go by or when I was unduly worried about meeting a deadline. I will miss working with each of you. The Review Editors (who edit and put together the reviews that we publish in our six rubrics) and Assistant Editors (who evaluate and rank the submitted articles) are too numerous to name here. It is their work that allows our journal to function. My heartfelt thanks to all those who have served in one of those capacities over the years. It has been a privilege to work with you. Many thanks also to Jayne Abrate, AATF Executive Director, who supported and facilitated new French Review initiatives, such the Book Series or the Dossiers pédagogiques. [End Page 13] Kudos as well to our former Advertising Manager, Ann Sunderland, who until 2021 helped grease the financial wheels of our journal. In the March issue (Vol. 95.3), I offered a few parting thoughts about the day-to-day work at the French Review. I also included an addendum at the end of the "Articles" section of that issue, in the hope that it will be helpful to colleagues (particularly those at the beginning stages of their career) who plan to submit an article to our journal. In this issue, I would like to reiterate what I said about the need for universities and colleges to do more to recognize and support—instead of discouraging—their faculty members who are interested in joining the editorial team of a scholarly journal. Over the years, I have found that many colleagues were reluctant to serve in an editorial capacity at the French Review because the time involved is generally not taken into account in terms of tenure and promotion. It is counterproductive for universities and colleges to insist that faculty members produce a steady stream of published articles while doing little or nothing to support those who serve at the journals in which articles are published. In other news, after nearly two years of declining submissions, this past academic year has seen a slight increase in the number of articles that are submitted to our journal, especially since early December (as usual, the final numbers will be provided in the October issue). Of course, it remains to be seen if that trend will last. The decline in submissions was probably one of the consequences of the...

Necessity of Framing Virtuous Journal Policies for Attaining High Impact Citations

In the era of modern science and technology research has been given great significance. This will be only possible in light of accurate results extracted from good quality published researches in reputed journals. To ensure quality standard maintenance of medical journals, recommended international guidelines by International Committee for Medical Journal Editors (ICMJE), World Association of Medical Editors (WAME), and Committee of Publication Ethics (COPE) must be followed. All these will be emphasize various steps for publications i.e. pre submission phase, submission phase, publication proceedings and post publication phase. The ICMJE and WAME is comprised of a group of medical journal editors and the legislatures of associated organizations. They focus to refine the recommendations for the conduct, reporting, editing and publication of scholarly work in medical journals.1,2 While aim of COPE is to focus on publication ensuring maintenance of all ethical rights of subjects and patients especially in line with Helsinki declaration.3-5 Following and strict adherence to all these will be helpful to achieve good Global ranking of a journal. This will be done by SC Imago Journal Rank (SJR) which is an internationally recognized standard for recognizing the quartile (Q) of a journal. All the mile stones for this ranking and quartile demarcation, includes the overall number of published manuscripts, total number of citations, and average citations per week. Regarding quartiles, they helps in journal’s ranking for impact factor or impact index. Q1 comprises of upper 25% of journals in the gradient, Q2 involves journals in next 25 to 50% group, Q3 includes journals between 50 to 75% groups. While Q4 is occupied by group of journals between 75 to 100%. The esteemed journals of specific discipline are usually the ones which can occupy first quartile, Q1.6 In light of ICMJE, WAME and COPE guidelines, following can be the plan to uplift a medical journal in view to make it a Q1 journal;1-3 There must be clarity for each an ever policy to run a medical journal in successful way. Highlighted amongst those policies includes finalization of journal’s name reflecting the content to be published. Then comes establishment of editorial board i.e. editor in chief, associate editors, assistant editors, advisory board, statistician, English language expert and team for plagiarism and software handling. The editors should be highly reputed individuals who are capable of making decisions regarding the acceptance or rejection of an article. He should have the ability to work as a team, because he is the one to regular involve author’s reviewers and publishers in the process of printing the journal.

From the Editors’ Desk

From the Editors’ Desk

Editors' Note

Editors' Note Red Washburn and Brianne Waychoff bell hooks states, "Love is an action, never simply a feeling." This issue, Black Love, arrives during a critical moment in the ongoing struggle for racial justice. With the political urgency of the Movement for Black Lives, prison abolition, cops out of Pride, decolonize the curriculum, and bell hooks joining the ancestors, we remember love is a verb. We use this vision to help us imagine a better life in which love transcends rigid concepts of romantic coupledom under capitalism, and instead, expands the thought and practice of love as a community project of mutual aid, trust, care, kindness, compassion, respect, and solidarity across the spectrum of difference. The politics of love holds much promise for honoring self-care, educating for critical consciousness, and promoting social change. Love allows us to hold space for Black people to heal under white supremacy, cisheteropatriarchy, and capitalism, as well as move toward a collective social responsibility to build a better world where we all are free. The guest editors, writers, and artists who contributed to this issue explore the knowledge/power of Black love from different angles of vision that enrich this interdisciplinary area of study in exciting ways. We are indebted to the guest editors Mary Frances Phillips, Rashida L. Harrison, and Nicole M. Jackson for convening this issue. We are delighted to feature work on Black love, nationally and transnationally, ranging from the United States to Nigeria, as well as Trinidad and Tobago. We commend the stellar academic essays on social movements, self-care, and cultural productions, especially centering the writings of Toni Morrison and Audre Lorde. We celebrate the stunning creative writing and visual art by Arisa White, Roya Marsh, and Mel Michelle Lewis, among other notable contributors. We are grateful for this scholarship and activism. We want to thank WSQ, including the editorial board; poetry, prose, and [End Page 10] art editors; and editorial assistants. In particular, we want to extend a tremendous thank-you, thank-you, thank-you to the editorial assistants, Amy Iafrate, Alex Johnson, Joe Goodale, Ivy Bryan, Googie Karrass, and Kayla Reece, all of whom worked tirelessly on communicating with the scholars, writers, and artists to make this issue happen. In addition, we want to extend a very generous thank-you to Dána-Ain Davis, Director of the Center for the Study of Women in Society, and administrative staff Eileen Liang and Jennifer Bae for providing WSQ with internships in feminist publishing for graduate students in women's and gender studies at the City University of New York. Our partnership has significantly enriched the quality of the journal for our feminist communities across CUNY and beyond. We are greatly indebted to the Feminist Press for all its help with scheduling, copyediting, and distributing our issues, especially to Interim Executive Director Lauren Rosemary Hook and Assistant Editor Nick Whitney. We cannot thank you enough for your help and support. We also wish to thank Associate Director of the Center for the Humanities Kendra Sullivan, as well as Jordan Lord and Sampson Starkweather for collaborating with us and building a new vision for the journal, including aiding with publicity and administrative matters. We acknowledge the support we have received from President Kaye Wise Whitehead and Former Interim Executive Director Jen Ash of the National Women's Studies Association, as well as the Community of Literary Magazines and Presses (CLMP). Lastly, we want to thank each other as general editors of WSQ for continuing this work during a global pandemic with much loss and grief. We are looking forward to celebrating fifty years of WSQ and the future of this important feminist journal. Red Washburn Kingsborough Community College Director of Women's and Gender Studies Associate Professor of English City University of New York Brianne Waychoff Borough of Manhattan Community College Associate Professor of Speech Communications and Theatre Arts, Gender and Women's Studies Program City University of New York Works Cited hooks, bell. 2001. All About Love: New Visions. New York: William Murrow. Google Scholar Copyright © 2022 Red Washburn and Brianne Waychoff

Congratulations New Assistant Editors and Distinguished Reviewers

Congratulations New Assistant Editors and Distinguished Reviewers

Rethinking, Narrating, Consuming Modern and Contemporary Southeast Asia

As this special issue would not have been possible without the generosity of certain individuals during these most trying times, this modest introduction must necessarily begin with gratitude. My co-editor, Yue Zhang, and I would like to express our sincerest thanks to the tireless and gracious people behind Rupkatha. It is because of their vision and efforts that Rupkatha has become a truly global journal of interdisciplinary Humanities, a home to many ideas that challenge and extend the borders of what it means to do Humanistic research in order to all the more properly respect its integrity. We hope that this special issue that features works from and about the East and Southeast Asian regions, along with their associated diasporic communities, will contribute to the noble vision of Rupkatha. We extend our gratitude to the numerous scholars who shared their expertise as peer-reviewers and whose generosity ensured the success of this special issue. We are also very grateful to our editorial assistants Mr. John, Fong Chi Chon and Mr. Chris, Miao Chi both of whom often went above and beyond the call of duty to ensure the smooth production of this special issue. Of course, we must also thank all those scholars, both established and up-and-coming, who responded to our call for submissions. The response to this special issue could only be described as overwhelmingly robust, which is indicative of the unquestionable vigor in the field of contemporary East and Southeast Asian literary and cultural studies. Indeed, the sheer diversity of the submissions makes it a challenge to collectively introduce the essays without the risk of taking away from their inevitable multiplicity by imposing an artificial thematic unity. Thus, while the concerns of the essays included in this issue cannot be fully contained within their assigned thematic categories, and by no means should be read exclusively within such, I shall nevertheless risk grouping them based on what I conceive to be their principal critical concern—that is to say, rethinking, narrating, consuming.

Kawasaki Disease Outcomes: It's Not Just the Heart!

Kawasaki Disease Outcomes: It's Not Just the Heart!